Mursla Bio unveils new bead-nanochip technology for ultrasensitive and high throughput EV detection

Cambridge, UK, 13th April 2022: Mursla Bio, a novel multi-omics Extracellular Vesicle (EV) characterisation company, is pleased to present its novel nanochip-based technology, as detailed in the pre-print* ‘An electro-optical bead-nanochip technology for the ultrasensitive and multi-dimensional detection of small extracellular vesicles and their markers’, published today. This technology is part of Mursla Bio’s ExoPheno™ platform.

Key features of the technology include:

  • Ultrasensitive detection of target EVs and their markers.
  • Compatibility with clinical practices in a high throughput format.
  • Determination of novel exosome dimensions enabling new research and clinical applications.
  • Presentation of a roadmap for near absolute target EV quantification and single EV detection.

This ultrasensitive technology is called NEXOS (Nanoparticle EXOsome Sensing). It comprises two methods, the first is a novel patented and scalable nanoelectronics method, E-NEXOS, and the second, a high-throughput optical detection method, O-NEXOS. Both share the same steps for the immunocapture and antibody-labelling of extracellular vesicles and can be combined to derive differentiated detection parameters.

Dr Tomás Dias (PhD), CTO, Mursla Bio commented: “To advance the understanding of EVs’ biology and their implications in disease, novel tools are required. NEXOS technology offers ultrasensitive and original characterisation metrics with the aim of disrupting many EV applications. The reported study is the result of work carried out by Mursla’s multidisciplinary team.

NEXOS is part of Mursla Bio’s ExoPheno™ platform and was engineered to improve the translation of EV-based diagnostics into clinics.

Pierre Arsène, Founder and CEO, Mursla Bio added: “We believe that properly analysing EV biology in patients leads to breakthrough diagnostic solutions. It is now an engineering problem and our new nanoelectronics-based technology contributes to overcoming the last technical hurdles around sensitivity and clinical compatibility.

* Pre-prints are used to increase the speed of scientific communication and are generally subsequently submitted to peer-review journals.


Contact: Mursla Bio

Sarah Brereton, Director, Limewash
Tel: 07796 583 223

About Mursla Bio
Mursla Bio is a breakthrough Extracellular Vesicle (EV) characterisation company based on a novel proprietary technology platform, ExoPheno™, which detects the multi-omics cargo of tissue-specific EVs in blood for various biomedical applications. Extracellular Vesicles have been shown to reflect the state of their cellular sources, transporting specific ‘-omics’ information (DNA, RNA, proteins, lipids and metabolites) either locally or to distant sites via the circulatory system, including blood.

Discover more:






Leave a Reply